Viking Therapeutics Inc
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
During the three months ended March 31, 2024, we satisfied certain U.S. federal and state tax withholding obligations due upon the vesting of restricted stock unit awards by automatically withholding from the shares being issued in connection with such award a number of shares of our common stock with an aggregate fair market value on the date of vesting equal to the minimum tax withholding obligations. The following table sets forth information with respect to shares of our common stock withheld by us to satisfy certain tax withholding obligations during the quarter ended March 31, 2024:
| Total Numberof SharesPurchased · AveragePrice Paid perShare · Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs · Maximum Number(or Approximate DollarValue) of Shares that May Yet bePurchased Under thePlans or Programs | ||||||
|---|---|---|---|---|---|---|
| January 1, 2024 – January 31, 2024 | (422,613) | (1) | $17.61 | — | $47,556,793 | (2) |
| February 1, 2024 – February 29, 2024 | — | — | — | 47,556,793 | (2) | |
| March 1, 2024 – March 31, 2024 | (411,098) | $84.30 | — | — | (2) | |
| Total | (833,711) | $50.49 | — | $— | ||
(1) Represents shares of our common stock withheld from employees for the payment of taxes.
(2) On March 10, 2022, our board of directors authorized a stock repurchase program effective March 18, 2022, whereby we could purchase up to $50.0 million in shares of our common stock over a period of up to two years (the “Repurchase Program”). The Repurchase Program was to be carried out at the discretion of a committee of our board of directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades or in privately negotiated transactions. We did not repurchase any shares of our common stock under the Repurchase Program during the quarter ended March 31, 2024 and the Repurchase Program expired on March 18, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.